Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000895421-25-000463
Filing Date
2025-08-06
Accepted
2025-08-06 14:13:20
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 7952
2 EXHIBIT NO. 99.1 TO SCHEDULE 13G JOINT FILING AGREEMENT EXHIBIT_NO.99.1.txt EX-99.1 CHARTER 1392
3 EXHIBIT NO. 99.2 ITEM 7 INFORMATION EXHIBIT_NO.99.2.txt EX-99.2 OPIN COUNSEL 686
  Complete submission text file 0000895421-25-000463.txt   12022
Mailing Address 1585 BROADWAY NEW YORK NY 10036
Business Address 1585 BROADWAY NEW YORK NY 10036 212-761-4000
MORGAN STANLEY (Filed by) CIK: 0000895421 (see all company filings)

EIN.: 363145972 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6211 Security Brokers, Dealers & Flotation Companies
(CF Office: 02 Finance)

Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Subject) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91724 | Film No.: 251188917
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)